Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Beyond 5 years Francis F. Lopez, MD Medical Oncology Bakit 5 years???? Risk of Recurrence 10 year over-all survival by stage Outline Cancer treatment-induced bone loss (CTIBL) Overweight and obesity Contra-lateral breast cancer Cardiac Complications from Irradiation Neurologic complications Cancer treatmentinduced bone loss Bone is a dynamic tissue undergoing resorption and formation throughout life resulting in a net bone balance In osteoporosis, resorption usually exceeds formation with the net effect of bone loss, decreased strength, and an increased risk of fracture Cause: hormone depletion promotes osteoporosis and increases the risk of fracture Hormone depletion (hypogonodal) state induced by cancer therapies Premature menopause resulting from chemotherapy Deliberate ovarian ablation Hypoestrogenemia secondary to aromatase inhibitors (arimidex, femara and aromasin) Chemotherapy chemotherapy Bone loss with chemotherapy extends to postmenopausal women, suggesting that chemotherapy has a direct effect on bone • American Journal of medicine 114:653-659, 2003 Aromatase inhibitors (AI) Women treated with AI were 2.5 times more likely to suffer a fracture compared to women treated with tamoxifen Fracture Risk Following end of treatment fracture rates were similar in both groups (RR=0.98 (0.81-1.32), p=0.5 J. Cuzick on behalf of ATAC/LATTE Trialists’ Group. Poster presented at 12th Milan Breast Cancer Conference 2010 Major risk factors for osteoporosis and fracture Prior fragility fracture (>40 years of age) Age (>65 years) Low bone mineral density (T-score < -2.5) Family history of osteoporotic fracture Vertebral compression fracture Osteopenia apparent on x-ray film Hypogonadism Early menopause (before age 45) Minor risk factors for osteoporosis and fracture Rheumatoid arthritis Low dietary calcium intake Smoker Excessive alcohol intake Excessive caffeine intake (>4 cups/day) Weight (<120 pounds) Weight loss > 10% of weight at age 25 Diagnostic tests Dual energy x-ray absoptiometry (DXA) scans at baseline (bone density) Thoracic and lumbar spine x-ray to rule out vertebral fracture in patients with kyphosis, historical height loss > 6cm, acute incapacitating back pain syndrome, and in patients 65 years and older Follow-up: DXA scans every 1-2 years Treatment “bone hygiene” measures: lifestyle modification that promotes bone health: Calcium 1000mg per day Vitamin D 800IU per day Smoking cessation modest alcohol intake (<2 units per day) Increase exercise activity Overweight and Obesity Excuses for Weight Gain Masarap kumain Tamad Busy Ideal Body Weight kg + 2.3 x (height in inches – 60) Example: 45.5 + 2.3 x (62 inches – 60) 45.5 + 2.3 x 2 45.5 + 4.6 = 50kg or 110 pounds Overweight > 121 pounds Obese > 132 pounds 45.5 Obesity and breast cancer Poor prognostic characteristics on diagnosis: larger tumor, grade III and more positive lymph nodes Poor prognosis: affects over-all survival and disease free survival Increased risk of contralateral breast cancer, loco-regional recurrence and other primary cancers Diet and Exercise Healthy Lifestyle: Five or more servings (dakot o sandok) of 5 different kinds of fruits and vegetable (VF) per day Physical activity (PA): Walking 30 minutes per day 6 days per week Healthy Lifestyle and Mortality High VF/high PA: 4.8% Low VF/high PA: 10.4% High VF/low PA: 10.7% Low VF/low PA: 11.5% 10 year survival High VF/high PA = 93% Other groups: 86% to 87% Therefore, gain 6% to 7% absolute risk reduction in mortality at 10 years high VF/high PA Observed in both obese and non-obese Contra-lateral Breast cancer Incidence From 1975 through 2006: 339,790 diagnosed with (first) breast cancer 12,886 or 4% developed invasive breast cancer in the contra-lateral breast 40% occurred within the 1st to 4th year of the first breast cancer diagnosis 30% between the 5th to 9th year 30% 10 years or later Estrogen Receptor in 2nd breast cancer First 67% were still ER+ First ER+ breast cancer ER- breast cancer 40% were ER+ 43% were ER- Prophylactic mastectomy (PM) Majority not high risk and 13% were high risk (gene mutation) Low risk group: Contralateral breast cancer No PM (0.5%) PM 0% Low risk group: Distant metastasis No PM 7% (2 to 3 years) PM 4% Cardiac Complications from Irradiation Neurologic Complications Irradiation to the left breast: not associated with higher risk of cardiac death up to 20 years Cognitive and memory loss (chemo brain) resolves a few years after treatment Thank you!